Clarifying the Discussion Points in New Drug Application Reviews for Approval in Japan by a Government Advisory Council

Abstract

Background:

In Japan, the Pharmaceutical Affairs and Food Sanitation Council (PAFSC) of the Ministry of Health, Labour and Welfare conducts discussions during the final stages of drug application reviews based on reports from the Pharmaceuticals and Medical Devices Agency (PMDA). Any disagreements or points of contention raised during these discussions can result in delays to drug approval. It is therefore important to characterize the points of discussion in the PAFSC meetings to optimize the process and enable more efficient drug approval reviews in Japan.

Methods:

We investigated the recorded minutes of PAFSC meetings concerning 229 drug applications (comprising 164 new drug applications and 65 supplemental applications) between fiscal years 2012 and 2014. The discussion points were characterized according to their main topics, and the frequency of each topic was examined.

Results:

Clinical trials were the most frequent topic of discussion. Issues concerning package inserts were also prominent because many required reconsiderations and follow-up after council meetings. In particular, additional precautions and further clarification regarding drug indications and dosage were major points for reconsideration and follow-up.

Conclusions:

The review process may be improved if the points identified in this study are taken into consideration during the drug review process by the PMDA.

Keywords

new drug applications regulatory science advisory council package inserts

Get full access to this article

View all access options for this article.

References

Arthur

Robyn

Daniel

. The Food and Drug Administration advisory committees and panels: how they are applied to the drug regulatory process. Am J Gastroenterol. 2014;109:1508–1512.

Ministry of Health, Labour and Welfare. Regulations of Pharmaceutical Affairs Council [in Japanese]. http://www.mhlw.go.jp/file/05-Shingikai-11121000-Iyakushokuhinkyoku-Soumuka/0000072285.pdf. Accessed January 13, 2017.

Pharmaceutical and Medical Devices Agency. PMDA review reports: drugs [in Japanese]. http://www.pmda.go.jp/PmdaSearch/iyakuSearch/, Accessed on January 13, 2017.

Jeffrey

Seth

Navjot

Philip

. FDA advisory committee meeting outcomes. Nat Rev Drug Discov. 2012;11:513–514.

Tibau

Ocana

Anguera

. Oncologic Drugs Advisory Committee recommendations and approval of cancer drugs by the US Food and Drug Administration. JAMA Oncol. 2016;2:744–750.

Pharmaceutical and Medical Devices Agency. Annual report FY 2015. https://www.pmda.go.jp/files/000214925.pdf. Accessed January 13, 2017.

Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare. On the standard review timeline for new drug applications. https://www.pmda.go.jp/files/000153667.pdf. Published March 30, 2012. Accessed January 13, 2017.

Ministry of Health, Labour and Welfare. First or second Committee on New Drugs of Pharmaceutical Affairs and Food Sanitation Council (PAFSC) [in Japanese]. http://www.mhlw.go.jp/stf/shingi/shingi-yakuji.html?tid=127851. http://www.mhlw.go.jp/stf/shingi/shingi-yakuji.html?tid=127852. Accessed January 13, 2017.

Pharmaceutical and Medical Devices Agency. Package inserts, prescription drugs [in Japanese]. http://www.pmda.go.jp/PmdaSearch/iyakuSearch/. Accessed January 13, 2017.

10.

Otsubo

Asahina

Noguchi

. Similarities and differences between US and Japan as to pharmacogenomic biomarker information in drug labels. Drug Metab Pharmacokinet. 2012;27:142–149.

11.

Ministry of Health, Labour and Welfare. List of the first or second Committee on New Drugs of Pharmaceutical Affairs and Food Sanitation Council members [in Japanese]. http://www.mhlw.go.jp/file/05-Shingikai-11121000-Iyakushokuhinkyoku-Soumuka/0000132975.pdf, http://www.mhlw.go.jp/file/05-Shingikai-11121000-Iyakushokuhinkyoku-Soumuka/0000132979.pdf. Published July 29, 2016. Accessed January 13, 2017.

12.

Ministry of Health, Labour and Welfare. For over-the-counter drugs and the poison [in Japanese]. http://www.mhlw.go.jp/file/05-Shingikai-11121000-Iyakushokuhinkyoku-Soumuka/0000014658.pdf. Published August 8, 2013. Accessed January 13, 2017.

13.

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Q5A (R1)-Q5E Guidelines Quality of Biotechnological Products. http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html. Accessed January 13, 2017.

14.

Christian

Gabriele

. Typical pitfalls in applications for marketing authorization of biotechnological products in Europe. Nat Rev Drug Discov. 2008;7:893–899.

15.

Kanmuri

Narukawa

. Characteristics of post-marketing studies and their contribution to post-marketing safety measures in Japan. Pharma Med. 2014;28:67–73.

16.

Ishiguro

Takeuchi

Uyama

. The MIHARI project: establishing a new framework for pharmacoepidemiological drug safety assessments by the Pharmaceuticals and Medical Devices Agency of Japan. Pharmacoepidemiol Drug Saf. 2016;25:854–859.

17.

Ueda

Sato

Yasuhara

. Study on package insert of ethical drug and its described manner. Health and Labour Sciences Research Grant (FY2008-2010) [in Japanese]. http://mhlw-grants.niph.go.jp/niph/search/NIDD00.do?resrchNum=201034007B. Accessed January 13, 2017.